Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
PL02 - Innovation to Bridge Lung Cancer Care Tomorrow (Japanese, Mandarin, Spanish Translation Available)
- 07:00 - 09:00
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
-
+
PL02.01 - Chair
07:00 - 07:00 | Presenter: Clarissa Mathias
- Abstract
No abstract available for this presentation
-
+
PL02.02 - Chair
07:00 - 07:00 | Presenter: James Chih-Hsin Yang
- Abstract
No abstract available for this presentation
-
+
PL02.03 - Human Data Science and the Omics Revolution: What Does It Mean for Oncology Patients?
07:00 - 07:20 | Presenter: Patrick Tan
- Abstract
No abstract available for this presentation
-
+
PL02.05 - Challenges in Clinical Application of Precision Medicine: From Targeted Therapies to Immunotherapy: Advanced Non-Small Cell Lung Cancer (NSCLC) as a Model
07:20 - 07:40 | Presenter: David R. Gandara
- Abstract
Loading... -
+
PL02.06 - Patient-Directed Innovation, Research and Clinical Trials
07:40 - 08:00 | Presenter: Lisa C Goldman
- Abstract
Loading... -
+
PL02.07 - Translational Medicine: An Engine of Change for Bringing New Technology to the Community
08:00 - 08:20 | Presenter: Michael Boyer
- Abstract
Loading... -
+
PL02.08 - Live Q&A
08:20 - 09:00
- Abstract
No abstract available for this presentation
-
+
ES01 - Choosing Systemic Therapies After Chemoimmunotherapy in NSCLC
- 09:15 - 10:15
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
ES01.01 - Non-Squamous
09:15 - 09:35 | Presenter: Virote Sriuranpong
- Abstract
No abstract available for this presentation
-
+
ES01.02 - Choosing Systemic Therapies After Chemoimmunotherapy – Squamous
09:35 - 09:55 | Presenter: Claudio Marcelo Martin
- Abstract
Loading... -
+
ES01.03 - Systemic Therapy after Chemo IO in Small Cell Lung Cancer
09:55 - 10:15 | Presenter: Charu Aggarwal
- Abstract
No abstract available for this presentation
-
+
OA01 - Established Drugs in Special Populations and New Drugs in Established Populations
- 09:15 - 10:15
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Immunotherapy (Phase II/III Trials)
-
+
OA01.01 - Chair
09:15 - 09:15 | Presenter: Noemi Reguart
- Abstract
No abstract available for this presentation
-
+
OA01.02 - Chair
09:15 - 09:15 | Presenter: Jiuwei Cui
- Abstract
No abstract available for this presentation
-
+
OA01.03 - Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
09:15 - 09:25 | Presenter: Saadettin Kilickap
- Abstract
Loading... -
+
OA01.04 - Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A
09:25 - 09:35 | Presenter: Fred R Hirsch
- Abstract
Loading... -
+
OA01.05 - Discussant
09:35 - 09:40 | Presenter: Edward B. Garon
- Abstract
No abstract available for this presentation
-
+
OA01.06 - Randomised Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR Mutant NSCLC
09:40 - 09:50 | Presenter: Gillianne Geet Yi Lai
- Abstract
Loading... -
+
OA01.07 - A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC
09:50 - 10:00 | Presenter: Matthew G. Krebs
- Abstract
Loading... -
+
OA01.08 - Discussant
10:00 - 10:05 | Presenter: Justin Gainor
- Abstract
No abstract available for this presentation
-
+
OA01.09 - Live Q&A
10:05 - 10:15
- Abstract
No abstract available for this presentation
-
+
OA02 - Updates in Locally Advanced NSCLC
- 09:15 - 10:15
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Locoregional and Oligometastatic Disease
-
+
OA02.01 - Chair
09:15 - 09:15 | Presenter: Kenichi Suda
- Abstract
No abstract available for this presentation
-
+
OA02.02 - Chair
09:15 - 09:15 | Presenter: Antoinette Wozniak
- Abstract
No abstract available for this presentation
-
+
OA02.03 - Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy in Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799
09:15 - 09:25 | Presenter: Martin Reck
- Abstract
Loading... -
+
OA02.04 - Randomized Phase Ⅱ Trial (RTOG1106) on Midtreatment PET/CT Guided Adaptive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer
09:25 - 09:35 | Presenter: Feng-Ming (Spring) Kong
- Abstract
Loading... -
+
OA02.05 - Local, Regional and Pulmonary Failures in the Randomised PET-Boost Trial for NSCLC Patients
09:35 - 09:45 | Presenter: Saskia Anne Cooke
- Abstract
Loading... -
+
OA02.06 - PSM Analysis Results from REFRACT: A Multi-Center Cohort Study Investigating the Treatment Patterns in EGFR-Mutant Unresectable LA- NSCLC
09:45 - 09:55 | Presenter: Nan Bi
- Abstract
Loading... -
+
OA02.07 - Discussant
09:55 - 10:05 | Presenter: You Lu
- Abstract
No abstract available for this presentation
-
+
OA02.08 - Live Q&A
10:05 - 10:15
- Abstract
No abstract available for this presentation
-
+
ES02 - Pro-Con: Do We Need Biomarkers to Guide the Choice of Immunotherapy Treatment?
- 10:30 - 11:30
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Immunotherapy (Phase II/III Trials)
-
+
ES02.01 - We Should Choose Treatment Based on PD-L1, TMB and Other Biomarkers
10:30 - 10:45 | Presenter: Ticiana A Leal
- Abstract
No abstract available for this presentation
-
+
ES02.02 - Immune Checkpoint Blockade for All NSCLC Regardless of PD-L1, TMB or Other Biomarkers
10:45 - 11:00 | Presenter: Naiyer Rizvi
- Abstract
No abstract available for this presentation
-
+
ES02.03 - We Should Use IO Alone as Maintenance
11:00 - 11:15 | Presenter: Roy S. Herbst
- Abstract
No abstract available for this presentation
-
+
ES02.04 - We Should Use Combination of IO and Chemotherapy as Maintenance
11:15 - 11:30 | Presenter: Marina Chiara Garassino
- Abstract
No abstract available for this presentation
-
+
ES03 - Understanding and Treating Oligometastatic Diseases
- 10:30 - 11:30
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Locoregional and Oligometastatic Disease
-
+
ES03.01 - Chair
10:30 - 10:30 | Presenter: Linda W Martin
- Abstract
No abstract available for this presentation
-
+
ES03.02 - Chair
10:30 - 10:30 | Presenter: Yasushi Nagata
- Abstract
No abstract available for this presentation
-
+
ES03.03 - Characterization and Classification of Oligometastatic Disease
10:30 - 10:42 | Presenter: Matthias Guckenberger
- Abstract
No abstract available for this presentation
-
+
ES03.04 - Timing of Systemic Therapy in OMD
10:42 - 10:54 | Presenter: Simon Ekman
- Abstract
Loading... -
+
ES03.05 - Surgery as a Component of Local Consolidative Therapy
10:54 - 11:06 | Presenter: Mara B Antonoff
- Abstract
Loading... -
+
ES03.06 - Radiation as a Component of Treatment for Oligometastatic Disease
11:06 - 11:18 | Presenter: Kevin Lee Min Chua
- Abstract
No abstract available for this presentation
-
+
ES03.07 - Live Q&A
11:18 - 11:30
- Abstract
No abstract available for this presentation
-
+
OA03 - Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC
- 10:30 - 11:30
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
OA03.01 - Chair
10:30 - 10:30 | Presenter: Jhanelle Elaine Gray
- Abstract
No abstract available for this presentation
-
+
OA03.02 - Chair
10:30 - 10:30 | Presenter: Sukhmani K. Padda
- Abstract
No abstract available for this presentation
-
+
OA03.03 - Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study
10:30 - 10:40 | Presenter: Alex I. Spira
- Abstract
Loading... -
+
OA03.04 - Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
10:40 - 10:50 | Presenter: Helena Yu
- Abstract
Loading... -
+
OA03.05 - Phase III Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
10:50 - 11:00 | Presenter: Atsushi Nakamura
- Abstract
Loading... -
+
OA03.06 - Discussant
11:00 - 11:10 | Presenter: Ignatius Ou
- Abstract
No abstract available for this presentation
-
+
OA03.07 - Live Q&A
11:10 - 11:30
- Abstract
No abstract available for this presentation
-
+
ES04 - Strategies to Increase Cure Rates in Stage III NSCLC: Optimising Checkpoint Inhibitors and Beyond
- 11:45 - 12:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Locoregional and Oligometastatic Disease
-
+
ES04.01 - Navigating the Evaluation of Novel Systemic Agents in Stage III Disease
11:45 - 12:05 | Presenter: Karen Kelly
- Abstract
Loading... -
+
ES04.02 - Biology Guided Adaptive Radiation Therapy (BigART) and Personalized Immunotherapy in Unresectable Stage
12:05 - 12:25 | Presenter: Feng-Ming (Spring) Kong
- Abstract
No abstract available for this presentation
-
+
ES04.03 - Extending Durvalumab Maintenance to Special Populations
12:25 - 12:45 | Presenter: Raffaele Califano
- Abstract
No abstract available for this presentation
-
+
MA01 - Novel Systemic Treatment in NSCLC
- 11:45 - 12:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
MA01.01 - Chair
11:45 - 11:45 | Presenter: Thanyanan Reungwetwattana
- Abstract
No abstract available for this presentation
-
+
MA01.02 - Chair
11:45 - 11:45 | Presenter: Julia K Rotow
- Abstract
No abstract available for this presentation
-
+
MA01.03 - The Role of Gut Microbiome in the Efficacy of Chemotherapy in Patients With Locally Advanced and Advanced Lung Cancer
11:45 - 11:50 | Presenter: Zhe Zhao
- Abstract
Loading... -
+
MA01.04 - A Randomized Study Comparing Cisplatin/Paclitaxel Liposome vs Cisplatin/Gemcitabine in Chemonaive, Advanced Squamous NSCLC
11:50 - 11:55 | Presenter: Caicun Zhou
- Abstract
Loading... -
+
MA01.05 - Clinical Efficacy and Safety of Pemetrexed With or Without Either Bevacizumab or Pembrolizumab in Patients With Metastatic NSCLC
11:55 - 12:00 | Presenter: Wang Chun Kwok
- Abstract
Loading... -
+
MA01.06 - Phase 2 of Pro-Autophagic Drug ABTL0812 in Combination With First-Line Paclitaxel and Carboplatin in IIIb/IV Squamous NSCLC
12:00 - 12:05 | Presenter: Joaquim Bosch-Barrera
- Abstract
Loading... -
+
MA01.07 - Discussant
12:05 - 12:10 | Presenter: Benjamin Levy
- Abstract
No abstract available for this presentation
-
+
MA01.08 - Gemcitabine Plus Capecitabine in Patients With Primary Pulmonary Lymphoepithelioma-Like Carcinoma Previously Treated With Chemotherapy
12:10 - 12:15 | Presenter: Ying Liang
- Abstract
Loading... -
+
MA01.09 - Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)
12:15 - 12:20 | Presenter: Saad A. Khan
- Abstract
Loading... -
+
MA01.10 - MDM2 Inhibitor APG-115 Suppresses Cell Proliferation and Tumor Growth in Preclinical Models Of NSCLC Harboring STK11 Mutations
12:20 - 12:25 | Presenter: Hao Sun
- Abstract
Loading... -
+
MA01.11 - CD47 Agonist Peptide PKHB1 Induced Cell Death in NSCLC via Triggering Endoplasmic Reticulum Stress
12:25 - 12:30 | Presenter: Jiani Ye
- Abstract
Loading... -
+
MA01.12 - Discussant
12:30 - 12:35 | Presenter: Will Lockwood
- Abstract
No abstract available for this presentation
-
+
MA01.13 - Live Q&A
12:35 - 12:45
- Abstract
No abstract available for this presentation
-
+
OA04 - New Data from Rare EGFR Alterations
- 11:45 - 12:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Targeted Therapy - Clinically Focused
-
+
OA04.01 - Chair
11:45 - 11:45 | Presenter: Hossein Borghaei
- Abstract
No abstract available for this presentation
-
+
OA04.02 - Chair
11:45 - 11:45 | Presenter: Jason Porter
- Abstract
No abstract available for this presentation
-
+
OA04.03 - Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations
11:45 - 11:55 | Presenter: Caicun Zhou
- Abstract
Loading... -
+
OA04.04 - Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer
11:55 - 12:05 | Presenter: Joshua K. Sabari
- Abstract
Loading... -
+
OA04.05 - Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
12:05 - 12:15 | Presenter: Kazuhiko Nakagawa
- Abstract
Loading... -
+
OA04.06 - Neratinib in Pretreated EGFR Exon 18-Mutant Non-Small Cell Lung Cancer (NSCLC): Initial Findings From the SUMMIT Basket Trial
12:15 - 12:25 | Presenter: Valentina Boni
- Abstract
Loading... -
+
OA04.07 - Discussant
12:25 - 12:35 | Presenter: Gillianne Geet Yi Lai
- Abstract
No abstract available for this presentation
-
+
OA04.08 - Live Q&A
12:35 - 12:45
- Abstract
No abstract available for this presentation
